PL3524260T3 - Kompozycje farmaceutyczne do leczenia braku apetytu - Google Patents

Kompozycje farmaceutyczne do leczenia braku apetytu

Info

Publication number
PL3524260T3
PL3524260T3 PL19161662.2T PL19161662T PL3524260T3 PL 3524260 T3 PL3524260 T3 PL 3524260T3 PL 19161662 T PL19161662 T PL 19161662T PL 3524260 T3 PL3524260 T3 PL 3524260T3
Authority
PL
Poland
Prior art keywords
inappetence
treatment
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
PL19161662.2T
Other languages
English (en)
Polish (pl)
Inventor
Bill ZOLLERS
Linda RHODES
Ernst Heinen
Gopinath DEVARAJ
Original Assignee
Elanco Animal Health Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elanco Animal Health Incorporated filed Critical Elanco Animal Health Incorporated
Publication of PL3524260T3 publication Critical patent/PL3524260T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/111Aromatic compounds
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/116Heterocyclic compounds
    • A23K20/132Heterocyclic compounds containing only one nitrogen as hetero atom
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/116Heterocyclic compounds
    • A23K20/137Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/10Feeding-stuffs specially adapted for particular animals for ruminants
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/20Feeding-stuffs specially adapted for particular animals for horses
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/40Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Feed For Specific Animals (AREA)
  • Dermatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL19161662.2T 2012-09-27 2013-09-27 Kompozycje farmaceutyczne do leczenia braku apetytu PL3524260T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261706164P 2012-09-27 2012-09-27

Publications (1)

Publication Number Publication Date
PL3524260T3 true PL3524260T3 (pl) 2023-11-27

Family

ID=50339468

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19161662.2T PL3524260T3 (pl) 2012-09-27 2013-09-27 Kompozycje farmaceutyczne do leczenia braku apetytu

Country Status (18)

Country Link
US (1) US11090292B2 (enExample)
EP (3) EP2906041A4 (enExample)
JP (2) JP6779618B2 (enExample)
KR (6) KR20230097201A (enExample)
CN (2) CN111419845A (enExample)
AR (2) AR092713A1 (enExample)
AU (2) AU2013323349B2 (enExample)
BR (1) BR112015006282B1 (enExample)
CA (1) CA2886091C (enExample)
DK (1) DK3524260T3 (enExample)
ES (1) ES2959427T3 (enExample)
MX (2) MX2015003564A (enExample)
NZ (2) NZ707174A (enExample)
PL (1) PL3524260T3 (enExample)
PT (1) PT3524260T (enExample)
RU (1) RU2648958C2 (enExample)
TW (3) TW202106298A (enExample)
WO (1) WO2014052780A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120131183A (ko) 2010-02-26 2012-12-04 라퀄리아 파마 인코포레이티드 악액질 치료용 그렐린 수용체 작용제
WO2013119800A1 (en) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
RU2648958C2 (ru) 2012-09-27 2018-03-28 Аратана Терапьютикс, Инк. Композиции и способы применения соединения для борьбы с отсутствием аппетита
WO2014144231A1 (en) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
KR20180108916A (ko) * 2015-01-28 2018-10-04 아라타나 세라퓨틱스, 인크. 체중-증량 화합물의 장기 사용을 위한 조성물 및 방법
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
AU2017358013B2 (en) * 2016-11-11 2020-08-06 Dsm Ip Assets B.V. Compositions and methods of pet food

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US193273A (en) * 1877-07-17 Improvement in material for pulley-covers
JP2893901B2 (ja) * 1990-09-07 1999-05-24 株式会社岐阜免疫研究所 動物用抗体含有油性ペースト製剤
CA2095786A1 (en) * 1992-05-08 1993-11-09 Franco J. Vaccarino Method of stimulating appetite
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
EP1181933A3 (en) * 2000-06-29 2002-04-10 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating or increasing appetite
US8309603B2 (en) * 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US20080171700A1 (en) * 2004-04-07 2008-07-17 Gastrotech Pharma A/S Use Of Secretagogue For The Teatment Of Ghrelin Deficiency
EP1812045A2 (en) * 2004-10-27 2007-08-01 Gastrotech Pharma A/S Uses of secretagogues for treatment of organ transplant patients
EP1956923A1 (en) * 2005-11-02 2008-08-20 Nestec S.A. Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use
CN101443358B (zh) * 2006-03-13 2016-05-11 利亚特·明茨 生长素释放肽剪接变体在治疗恶病质和/或压食和/或厌食-恶病质和/或营养不良和/或脂肪营养障碍和/或肌肉消耗和/或刺激食欲中的用途
ES2436419T3 (es) * 2006-09-27 2014-01-02 Ipsen Pharma S.A.S. Análogos de ghrelina sustituidos en el N terminal
JP2008127377A (ja) * 2006-11-24 2008-06-05 Jichi Medical Univ Ghs−r作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。
US20080226802A1 (en) * 2007-03-14 2008-09-18 Concentrate Manufacturing Company Of Ireland Beverage having natural sweeteners with one or more stevia components and source of berry
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
RU2007129408A (ru) * 2007-07-31 2009-02-10 Игорь Николаевич Жирков (RU) Способ выращивания поросят в период откорма
FR2920295B1 (fr) * 2007-09-05 2009-12-11 Desvac Dispositif d'injection de produits veterinaires a des volailles, comprenant un element de contention presentant une forme anatomique incluant des moyens de calage d'un os reperable
EP2215914B1 (en) * 2007-11-12 2013-04-24 San-Ei Gen F.F.I., INC. Method of improving sweetness qualities of stevia extract
JP5552481B2 (ja) * 2009-03-26 2014-07-16 武田薬品工業株式会社 ピラゾール化合物
KR20120131183A (ko) * 2010-02-26 2012-12-04 라퀄리아 파마 인코포레이티드 악액질 치료용 그렐린 수용체 작용제
RU2648958C2 (ru) 2012-09-27 2018-03-28 Аратана Терапьютикс, Инк. Композиции и способы применения соединения для борьбы с отсутствием аппетита

Also Published As

Publication number Publication date
CA2886091C (en) 2021-11-30
WO2014052780A3 (en) 2014-06-26
DK3524260T3 (da) 2023-10-09
ES2959427T3 (es) 2024-02-26
JP2018117625A (ja) 2018-08-02
TW202106298A (zh) 2021-02-16
KR20250048114A (ko) 2025-04-07
KR20230097201A (ko) 2023-06-30
TW201417812A (zh) 2014-05-16
CN105072909A (zh) 2015-11-18
AU2013323349B2 (en) 2016-09-15
BR112015006282B1 (pt) 2021-11-23
JP2016500660A (ja) 2016-01-14
EP3524260A1 (en) 2019-08-14
AU2016216741A1 (en) 2016-09-15
JP6796097B2 (ja) 2020-12-02
KR20220003640A (ko) 2022-01-10
RU2648958C2 (ru) 2018-03-28
NZ707174A (en) 2018-10-26
CN111419845A (zh) 2020-07-17
KR20150058345A (ko) 2015-05-28
MX2022015141A (es) 2023-02-01
KR20210009438A (ko) 2021-01-26
TWI667024B (zh) 2019-08-01
NZ746394A (en) 2019-01-25
JP6779618B2 (ja) 2020-11-04
EP4302825A2 (en) 2024-01-10
KR20190143484A (ko) 2019-12-30
EP2906041A4 (en) 2016-10-26
AU2013323349A1 (en) 2015-05-07
AR123902A2 (es) 2023-01-25
PT3524260T (pt) 2023-10-13
AU2016216741B2 (en) 2018-02-15
EP3524260B1 (en) 2023-09-13
US11090292B2 (en) 2021-08-17
WO2014052780A2 (en) 2014-04-03
EP4302825A3 (en) 2024-07-03
EP2906041A2 (en) 2015-08-19
BR112015006282A2 (pt) 2017-07-04
TW201924680A (zh) 2019-07-01
CA2886091A1 (en) 2014-04-03
RU2015114996A (ru) 2016-11-20
US20140088139A1 (en) 2014-03-27
MX2015003564A (es) 2015-11-16
AR092713A1 (es) 2015-04-29
TWI732158B (zh) 2021-07-01

Similar Documents

Publication Publication Date Title
HUE044611T2 (hu) Gyógyászati készítmény rák kezelésére
HUE045461T2 (hu) Gyógyászati készítmény rák kezelésére
ZA201501847B (en) Formulations of enzalutamide
ZA201407726B (en) Pharmaceutical compositions for combination therapy
LT2854768T (lt) Pemetreksedo farmacinės kompozicijos
ZA201503594B (en) Pharmaceutical compositions
PL2887924T3 (pl) Kompozycje farmaceutyczne etorykoksybu
PL3524260T3 (pl) Kompozycje farmaceutyczne do leczenia braku apetytu
LT2814473T (lt) Farmacinės kompozicijos, skirtos derinių terapijai
ZA201503552B (en) Pharmaceutical compositions of cetp inhibitors
PL3398594T3 (pl) Kompozycje do ulepszenia funkcji mózgu
IL217807A0 (en) Therapeutic compositions
GB201211153D0 (en) Pharmaceutical compositions
GB201100786D0 (en) Pharmaceutical compositions of immunosuppressants
ZA201409502B (en) Composition for treatment of warts
IL236870B (en) History of hydroxystatin for the treatment of osteoarthritis
EP2906536A4 (en) IMPROVED METHOD FOR PRODUCING A PERINDOPRIL INTERMEDIATE PRODUCT
HUE043019T2 (hu) Gyógyszerészeti készítmények kombinációs terápia céljára
GB201212717D0 (en) Treatment of musculoskeletal conditions
IL233740A0 (en) Treatment of liver diseases
PL2812351T3 (pl) Kompozycja farmaceutyczna do leczenia stwardnienia rozsianego
GB201219234D0 (en) Pharmaceutical compositions
GB201213303D0 (en) Pharmaceutical compositions
GB201204810D0 (en) Pharmaceutical compositions